Table 2.
Adipose tissue lymphocyte populations
| Castrate (n = 9) |
Low T/E (n = 9) |
Normal T/E (n = 8) |
Normal T/Low E (n = 10) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 4 | Baseline | Week 4 | Baseline | Week 4 | Baseline | Week 4 | P Value (Overall RM-ANOVA) | |
| T cells | |||||||||
| CD3+, cells/g AT | 155 (103) | 348 (288) | 93 (57) | 248 (236) | 138 (109) | 174 (125) | 203 (175) | 460 (643) | 0.74 |
| CD3+, %CD45+ cells | 10.2 (3.1) | 13.8 (5.3) | 8.6 (3.6) | 11.2 (5.0) | 10.9 (7.9) | 9.6 (1.8) | 10.4 (5.0) | 18.6 (15.6) | 0.88 |
| T-cell subsets | |||||||||
| Helper T cells | |||||||||
| CD4+, cells/g AT | 72 (45) | 164 (142) | 38 (20) | 119 (116) | 65 (52) | 89 (77) | 81 (56) | 233 (323) | 0.71 |
| CD4+, %CD3+ cells | 48.0 (8.0) | 47.4 (11.1) | 42.9 (8.3) | 47.9 (11.4) | 48.6 (10.4) | 47.3 (13.3) | 45.5 (12.2) | 49.9 (12.1) | 0.48 |
| Cytotoxic T cells | |||||||||
| CD8+, cells/g AT | 61 (46) | 126 (104) | 42 (33) | 101 (96) | 47 (34) | 58 (32) | 89 (107) | 174 (251) | 0.75 |
| CD8+, %CD3+ cells | 38.2 (10.5) | 36.7 (7.0) | 40.5 (11.2) | 40.7 (10.4) | 35.7 (6.7) | 36.6 (7.5) | 38.3 (12.1) | 36.3 (12.9) | 0.83 |
| B cells* | |||||||||
| CD20+, cells/g AT | 24 (17) | 38 (20) | 16 (12) | 32 (30) | 20 (17) | 30 (22) | 26 (29) | 40 (45) | 0.98 |
| CD20+, %CD45+ cells | 1.7 (1.1) | 1.4 (0.5) | 1.1 (0.6) | 1.8 (1.5) | 1.2 (0.8) | 1.3 (0.7) | 1.4 (1.1) | 1.8 (1.4) | 0.78 |
Data are shown as means (SD), and with cell numbers are presented in thousands. Baseline and end-of-treatment lymphocyte populations in adipose tissue (AT). P values represent time-by-group interactions from RM-ANOVA comparing all treatment arms at baseline and week 4.
*
B cells were quantified with myeloid cell populations, so subject number per group applies to T cells only; subject numbers from Table 3 apply to B cells.